<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461655</url>
  </required_header>
  <id_info>
    <org_study_id>LP0045-01</org_study_id>
    <secondary_id>2011-000244-24</secondary_id>
    <nct_id>NCT01461655</nct_id>
  </id_info>
  <brief_title>Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris</brief_title>
  <official_title>Exploratory Study Evaluating the Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris, Using a Split-Face Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this proof of principle study is to evaluate efficacy and safety of the sequential
      application of two marketed products for the treatment of acne vulgaris, using the Split-Face
      model
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Inflammatory Lesions From Baseline to End of Treatment</measure>
    <time_frame>Baseline to End of treatment (4 weeks)</time_frame>
    <description>Percentage change in inflammatory lesions count from baseline to the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-inflammatory Lesions Count</measure>
    <time_frame>Baseline to End of treatment (4 weeks)</time_frame>
    <description>Percentage change in non-inflammatory lesions count from baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Lesions Count</measure>
    <time_frame>Baseline to End of treatment (4 weeks)</time_frame>
    <description>Percentage change in total lesions count from baseline to the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Lesions Count</measure>
    <time_frame>Baseline to Day 8</time_frame>
    <description>Percentage change in total leasions count from baseline to day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Lesions Count</measure>
    <time_frame>Baseline to Day 15</time_frame>
    <description>Percentage change in total lesions count from baseline to day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Total Lesions Count</measure>
    <time_frame>Baseline to Day 22</time_frame>
    <description>Percentage change in total lesions count from baseline to day 22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment (IGA) of Disease Severity</measure>
    <time_frame>Baseline to End of treatment (4 weeks)</time_frame>
    <description>The investigator made an assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear, Almost clear, Mild, Moderate, Severe, and Very severe).
The outcome was the proportion of &quot;success&quot; (improvement of two grades of the IGA) from baseline to the end of treatment. &quot;Success&quot; is defined as improvement of two grades from the baseline assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Topical retinoid - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical retinoid-NSAID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>marketed topical retinoid</intervention_name>
    <description>once daily application, 4 weeks</description>
    <arm_group_label>Topical retinoid-NSAID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>marketed topical NSAID</intervention_name>
    <description>once daily application, 4 weeks</description>
    <arm_group_label>Topical retinoid-NSAID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vehicle gel</intervention_name>
    <description>once daily application, 4 weeks</description>
    <arm_group_label>Topical retinoid - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>marketed topical retinoid</intervention_name>
    <description>once daily application, 4 weeks</description>
    <arm_group_label>Topical retinoid - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects having understood and signed an informed consent form

          -  Male or female subjects who are 18 to 35 years (both included) of age presenting acne
             vulgaris of the face.

          -  A minimum of 10 inflammatory lesions (papules and pustules) on the entire face, and a
             minimum of 20 non-inflammatory lesions (open comedones and closed comedones) on the
             entire face.

          -  Disease severity grade as mild or moderate according to the investigator's global
             assessment (grade 2 or grade 3)

        Exclusion Criteria:

          -  Females who are pregnant, of child-bearing potential and who wish to become pregnant
             during the study, or who are breast feeding.

          -  Subjects with any acne cysts or more than one nodule per hemiface.

          -  Subjects with acne conglobata, acne fulminans, secondary acne (e.g. chloracne,
             drug-induced acne), or any acne requiring systemic treatment.

          -  Subjects with a dark pigmentation of the skin or skin type that may, in any way,
             confound interpretation of the study results (skin type V or VI on Fitzpatrick scale.

          -  Subjects with other facial skin disorders that may interfere with study assessments.

          -  Subjects who will use medicated cosmetics and/or soaps (including soaps containing
             antibacterial agents such as benzoyl peroxide, keratolytic agents such as salicylic
             acid, skin fresheners/astringents or aftershave products) on the face for the duration
             of the study.

          -  Subjects with a history of actinic keratosis on the face or skin cancer.

          -  Use of hormonal oral contraceptives for acne control for less than 6 months prior to
             the randomisation.

          -  Subjects using one of the following systemic medication within 4 weeks before the
             randomisation and during the study, which could have an effect on the trial disease.

          -  systemic corticosteroids,

          -  anti-acne drugs,

          -  oral retinoids

          -  any immunosuppressive drugs.

          -  Subjects using systemic NSAIDs (including aspirin) within 1 week before the
             randomisation and during the study.

          -  Subjects using paracetamol within 1 week before the randomisation. Paracetamol will be
             allowed during the study with a maximum dose of 1g twice daily and for a maximum of 3
             consecutive days

          -  Subjects using one of the following topical medication within 2 weeks before the
             randomisation and during the study, which could have an effect on the trial disease:

          -  anti-inflammatory drugs (e.g. topical corticosteroids, NSAIDs),

          -  anti-acne drugs,

          -  topical retinoids,

          -  topical antibacterial agents

          -  any topical immunosuppressive drugs.

          -  Subjects with known or suspected hypersensitivity to component(s) of the
             investigational products or other nonsteroidal anti- inflammatory drug NSAIDs (e.g.,
             aspirin, diclofenac, ibuprofen, ketoprofen).

          -  Subjects with presence of any clinically significant gastrointestinal pathology (e.g.
             chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms
             (e.g. diarrhea, vomiting).

          -  Subjects with known presence of active peptic ulcer.

          -  Subjects with history (during the last 10 years) or known presence of asthma.

          -  Subjects with history (during the last 5 years) or known presence of rhinitis or
             urticaria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Mrs Queille-Roussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Pharmacologie Clinique Applique a la Dermatologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CPCAD - Centre de Pharmacologie Clinique Appliquée à la Dermatologie</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <results_first_submitted>April 17, 2013</results_first_submitted>
  <results_first_submitted_qc>October 7, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2013</results_first_posted>
  <last_update_submitted>December 30, 2016</last_update_submitted>
  <last_update_submitted_qc>December 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Start date: 21-NOV-2011 (FSFV - first subject first visit) Completion date: 26-APR-2012 (LSLV - last subject last visit)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Topical Retinoid - Placebo, Topical Retinoid - NSAID</title>
          <description>Using a left-right split face set up, the study evaluated the effect of sequential application of topical retinoid 0.1% gel and NSAID 5% gel in comparison with the sequential application of topical retinoid 0.1% gel and vehicle gel for the treatment of acne vulgaris.
The randomised subjects received the following products:
NSAID 5% gel , in the morning on the appropriate hemiface.
Topical retinoid 0.1% gel, in the evening on the entire face.
Vehicle gel, in the morning on the appropriate hemiface.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topical Retinoid - Placebo, Topical Retinoid - NSAID</title>
          <description>marketed topical retinoid : once daily application, 4 weeks
vehicle gel : once daily application, 4 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Inflammatory Lesions From Baseline to End of Treatment</title>
        <description>Percentage change in inflammatory lesions count from baseline to the end of treatment</description>
        <time_frame>Baseline to End of treatment (4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Retinoid - Placebo</title>
            <description>marketed topical retinoid : once daily application, 4 weeks
vehicle gel : once daily application, 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Retinoid-NSAID</title>
            <description>marketed topical NSAID : once daily application, 4 weeks
marketed topical retinoid : once daily application, 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Inflammatory Lesions From Baseline to End of Treatment</title>
          <description>Percentage change in inflammatory lesions count from baseline to the end of treatment</description>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.3" spread="45.3"/>
                    <measurement group_id="O2" value="-29.4" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-inflammatory Lesions Count</title>
        <description>Percentage change in non-inflammatory lesions count from baseline to the end of treatment</description>
        <time_frame>Baseline to End of treatment (4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Retinoid - Placebo</title>
            <description>marketed topical retinoid : once daily application, 4 weeks
vehicle gel : once daily application, 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Retinoid-NSAID</title>
            <description>marketed topical NSAID : once daily application, 4 weeks
marketed topical retinoid : once daily application, 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inflammatory Lesions Count</title>
          <description>Percentage change in non-inflammatory lesions count from baseline to the end of treatment</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.4" spread="31.2"/>
                    <measurement group_id="O2" value="-43.1" spread="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Lesions Count</title>
        <description>Percentage change in total lesions count from baseline to the end of treatment</description>
        <time_frame>Baseline to End of treatment (4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Retinoid - Placebo</title>
            <description>marketed topical retinoid : once daily application, 4 weeks
vehicle gel : once daily application, 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Retinoid-NSAID</title>
            <description>marketed topical NSAID : once daily application, 4 weeks
marketed topical retinoid : once daily application, 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Lesions Count</title>
          <description>Percentage change in total lesions count from baseline to the end of treatment</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.4" spread="24.0"/>
                    <measurement group_id="O2" value="-39.9" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Total Lesions Count</title>
        <description>Percentage change in total leasions count from baseline to day 8</description>
        <time_frame>Baseline to Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Retinoid - Placebo</title>
            <description>marketed topical retinoid : once daily application, 4 weeks
vehicle gel : once daily application, 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Retinoid-NSAID</title>
            <description>marketed topical NSAID : once daily application, 4 weeks
marketed topical retinoid : once daily application, 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Total Lesions Count</title>
          <description>Percentage change in total leasions count from baseline to day 8</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4" spread="24.1"/>
                    <measurement group_id="O2" value="-21.1" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Total Lesions Count</title>
        <description>Percentage change in total lesions count from baseline to day 15</description>
        <time_frame>Baseline to Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Retinoid - Placebo</title>
            <description>marketed topical retinoid : once daily application, 4 weeks
vehicle gel : once daily application, 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Retinoid-NSAID</title>
            <description>marketed topical NSAID : once daily application, 4 weeks
marketed topical retinoid : once daily application, 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Total Lesions Count</title>
          <description>Percentage change in total lesions count from baseline to day 15</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.9" spread="24.3"/>
                    <measurement group_id="O2" value="-22.2" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Total Lesions Count</title>
        <description>Percentage change in total lesions count from baseline to day 22</description>
        <time_frame>Baseline to Day 22</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Retinoid - Placebo</title>
            <description>marketed topical retinoid : once daily application, 4 weeks
vehicle gel : once daily application, 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Retinoid-NSAID</title>
            <description>marketed topical NSAID : once daily application, 4 weeks
marketed topical retinoid : once daily application, 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Total Lesions Count</title>
          <description>Percentage change in total lesions count from baseline to day 22</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.7" spread="21.8"/>
                    <measurement group_id="O2" value="-32.5" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Assessment (IGA) of Disease Severity</title>
        <description>The investigator made an assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear, Almost clear, Mild, Moderate, Severe, and Very severe).
The outcome was the proportion of &quot;success&quot; (improvement of two grades of the IGA) from baseline to the end of treatment. “Success” is defined as improvement of two grades from the baseline assessment.</description>
        <time_frame>Baseline to End of treatment (4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Retinoid - Placebo</title>
            <description>marketed topical retinoid : once daily application, 4 weeks
vehicle gel : once daily application, 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Topical Retinoid-NSAID</title>
            <description>marketed topical NSAID : once daily application, 4 weeks
marketed topical retinoid : once daily application, 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment (IGA) of Disease Severity</title>
          <description>The investigator made an assessment of the disease severity (Plaque thickening, Scaling and Erythema) using a 6-point scale (Clear, Almost clear, Mild, Moderate, Severe, and Very severe).
The outcome was the proportion of &quot;success&quot; (improvement of two grades of the IGA) from baseline to the end of treatment. “Success” is defined as improvement of two grades from the baseline assessment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from study start untill 43 (±2)days after the last on-treatment visit if an AE (serious or non-serious) classified as possible or probably related to the study treatment was ongoing at the last on-treatment visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Topical Retinoid - Placebo, Topical Retinoid - NSAID</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 6.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting or presenting a manuscript, the investigator shall provide to LEO Pharma a copy of all such manuscripts, and LEO Pharma shall have rights to review and comment. Upon the request of LEO Pharma the investigator shall remove any confidential information prior to submitting or presenting the manuscripts. The investigator shall, upon the request of LEO Pharma, delay publication or presentation to allow LEO Pharma to protect its inventions and other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

